In China, multiple myeloma treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and thalidomide—while the treatment for non-Hodgkin’s lymphoma (NHL) has Roche’s MabThera (rituximab) and Chipscreen’s Epidaza (chidamide) as central players. However, these premium-priced agents face different degrees of coverage and restrictions on use. Multiple emerging agents are in development for multiple myeloma and NHL. Although many of these emerging therapies appear clinically promising, they will face considerable competition from current agents and China’s reimbursement environment. Drawing on insights from 50 surveyed oncologists and hematologists and 3 interviewed payers in China, this Access & Reimbursement module assesses the dynamics affecting uptake of high-cost therapies for NHL and multiple myeloma and examines the market access challenges, and strategies to circumvent them, that emerging therapies will encounter in the next two to three years.